We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses a randomized, double-blind, parallel-group clinical trial investigating comparative safety and efficacy of different corticosteroid regimens for Duchenne muscular dystrophy. The abstract entitled ‘Comparative Safety and […]
Corticosteroids can improve muscle function in boys with Duchenne muscular dystrophy and are commonly prescribed for newly diagnosed patients. Dr Michela Guglieri (Newcastle University, Newcastle upon Tyne, United Kingdom) discusses the current unmet needs in DMD, and the role of corticosteroids in the treatment paradigm of DMD. The abstract entitled ‘Comparative Safety and Efficacy of […]
Functional neurological symptoms have been observed in young people globally during the COVID-19 pandemic, presenting with rapid onset of complex motor and vocal tic-like behaviours. Dr Davide Martino (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) discusses the rise in tic-like behaviour during the COVID-19 pandemic and what registry studies taught us about interventions of […]
Dr Else Charlotte Sandset, ESO Secretary General and Consultant Neurologist at the Stroke Unit, Department of Neurology, Oslo University Hospital, Norway, provides an overview of some of the high-quality research and scientific advances the stroke community can look forward to at the 8th European Stroke Organisation Conference (ESOC 2022) in Lyon, France and online from 4–6 May 2022.
Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses the key clinical highlights and hot topics in movement disorders and Parkinson’s disease. Questions: What are the key clinical highlights from the past year in the field of movement disorders and Parkinson’s disease? Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, […]
Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein […]
α-Synuclein conformations are discussed as potentially novel blood biomarkers in Parkinson’s disease (PD). Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss an ultrasensitive assay with antibodies directed against α-Synuclein multimers in blood, which may help to detect slight and early changes in this possible novel PD biomarker. […]
Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss the highlights from this year’s AD/PD 2022 conference. He discusses some of his personal highlights in the field of new therapeutics for neurodegeneration, and also the presentation of functioning MRI agents for α-Synuclein. Question: What are some of the […]
Get the latest clinical insights from touchNEUROLOGY